Showing results (461-470 of 472) with videos related to

Sort By:
Pageof 48
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 15, 2021
Combined PARP1-Targeted Nuclear Contrast and Reflectance Contrast Enhance Confocal Microscopic Detection of Basal Cell CarcinomaAditi Sahu, Jose Cordero, Xiancheng Wu, et al.
European Journal of Pharmacology|February 13, 2022
Unravelling the molecular mechanisms underlying chronic respiratory diseases for the development of novel therapeutics via in vitro experimental modelsChing Leng Tan, Yinghan Chan, Mayuren Candasamy, et al.
Open Biology|March 16, 2022
Molecular mechanisms of developmental pathways in neurological disorders: a pharmacological and therapeutic reviewNiraj Kumar Jha, Wei-Chih Chen, Sanjay Kumar, et al.
Nature Medicine|December 16, 2022
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanomaChelsea A Taylor, Robert A Watson, Orion Tong, et al.
NEJM Evidence|February 6, 2024
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder CancerKarim Chamie, Sam S Chang, Eugene Kramolowsky, et al.
Nature Communications|September 9, 2022
In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy responseAditi Sahu, Kivanc Kose, Lukas Kraehenbuehl, et al.
Chemico-Biological Interactions|October 18, 2021
Protein and peptide delivery to lungs by using advanced targeted drug deliveryDinesh Kumar Chellappan, Parteek Prasher, Vilashini Saravanan, et al.
The Journal of Urology|September 16, 2025
Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder CancerSam S Chang, Karim Chamie, Eugene Kramolowsky, et al.
The Journal of Urology|July 6, 2026
Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG In BCG-Unresponsive NMIBC with Carcinoma In Situ +/- Papillary DiseaseSam S Chang, Karim Chamie, Charles A Seabury, et al.
Nature Medicine|April 24, 2025
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockadeGusztav Milotay, Martin Little, Robert A Watson, et al.
Pageof 48